-
Reserpine (N1867): Practical Lab Workflow
2026-08-24
Reserpine (SKU N1867) provides a defined, high-purity research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and assay controls; the material is for research use only and is not intended for diagnostic, clinical, or veterinary applications.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike Binding
2026-08-24
The reference study shows that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike protein binding to host receptors, with effects determined by peptide length, receptor identity, and tyrosine modification. Its antibody-based binding experiments identify angiotensin (2–7) and related fragments as useful probes for investigating how renin-angiotensin signaling intersects with viral receptor engagement, while also highlighting important limits on biological interpretation.
-
Brefeldin A: From Trafficking Block to ER Stress
2026-08-23
Brefeldin A is more than a vesicle transport inhibitor: it is a temporal perturbation tool for connecting ER-to-Golgi traffic, protein quality control, and cancer-cell fate. This guide explains how to design and interpret BFA experiments using ER-stress adaptation as the central decision point.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-08-22
The reference study identified Merbromin as a selective mixed-type inhibitor of the SARS-CoV-2 3CLpro protease through activity-based screening, enzyme kinetics, binding analysis, and molecular docking. Its findings provide a biochemical starting point for inhibitor design while emphasizing the difference between target-level inhibition and demonstrated antiviral efficacy.
-
SINE-Induced XPO1 Degradation by Allostery
2026-08-22
The reference study shows that SINE inhibitors do more than block XPO1-mediated nuclear export: they remodel XPO1 to recruit the CRL substrate receptor ASB8 and trigger ubiquitin-dependent degradation. Cryo-EM, cellular turnover assays, and mechanistic validation define an allosteric degradation pathway that may explain how synthetic XPO1 inhibitors exploit a native cellular response.
-
Phosbind Biotin for Reliable Phosphorylation Analysis
2026-08-21
Phos binding reagent (Phosbind) Biotin, SKU F4001, supports sequence-independent Western Blot detection of phosphorylated proteins through dinuclear metal complex phosphate binding. This scenario-driven guide explains assay compatibility, reagent handling, interpretation, and practical vendor-selection considerations for researchers studying viability, proliferation, cytotoxicity, and signaling.
-
Microsecond Pulsed Fields and Mitochondrial Cardiac Ablation
2026-08-20
The reference study defines exposure conditions under which microsecond pulsed electric fields produce reliable cardiomyocyte ablation and links the effect to mitochondrial disruption and apoptosis-associated signaling. Its combination of dose-response testing, transcriptomics, ultrastructural imaging, and mouse validation provides a mechanistic framework for interpreting pulsed-field ablation beyond irreversible electroporation alone.
-
Nilotinib (AMN-107): From Kinase Control to Immune Reset
2026-08-20
Nilotinib (AMN-107) is best known for precise BCR-ABL pathway control, but emerging evidence positions it as a valuable tool for studying tumor immune visibility. This thought-leadership guide connects chronic myeloid leukemia research, gastrointestinal stromal tumor research, and colorectal cancer immunobiology through a practical translational framework.
-
Separating Growth Inhibition from Cancer Cell Death
2026-08-19
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from cell killing, including their differing magnitudes and temporal relationships, which can improve interpretation of in vitro drug screens.
-
Protoporphyrin IX: Heme and Photodynamic Research
2026-08-19
Protoporphyrin IX is the final heme-biosynthesis intermediate and a photodynamic compound with research relevance to fluorescence-based cancer diagnosis and photodynamic therapy. Its iron-chelation chemistry and light-dependent oxidative activity support mechanistic studies, but product handling, porphyria biology, and the distinction from ferroptosis require careful controls.
-
Carfilzomib (PR-171): From Proteasome Stress to Strategy
2026-08-18
Carfilzomib (PR-171) is more than a potent proteasome inhibitor: it is a translational tool for testing how irreversible proteasome-mediated proteolysis inhibition reshapes proteotoxic stress, apoptosis, and treatment response. This article connects its biochemical precision with preclinical evidence in multiple myeloma and esophageal cancer, then translates those insights into practical assay, combination, and biomarker strategies.
-
Sinapine Protects C2C12 Cells from ROS-Induced Death
2026-08-18
A 2024 study shows that sinapine protects C2C12 myoblasts from TBHP-induced oxidative cell death by reducing ROS accumulation and suppressing stress-activated kinase signaling linked to autophagy. Its inhibitor-based experiments provide a useful mechanistic framework for studying oxidative muscle injury while also highlighting the need to distinguish autophagy induction from impaired autophagic degradation.
-
ZIF-8–PEI Systems for mRNA Delivery and Storage
2026-08-17
This ChemRxiv preprint describes a ZIF-8 metal-organic framework strategy for encapsulating and delivering messenger RNA, with polyethyleneimine (PEI) added to reduce cargo leakage. The modified system supported protein expression in several cell lines and preserved functional mRNA after room-temperature storage, although the findings remain pre-peer-review and require broader validation.
-
Exo1 for Membrane Trafficking Assays
2026-08-17
Exo1 provides an acute, mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and secretion in cell-based workflows. Its value extends to tumor extracellular vesicle studies as a controlled trafficking perturbation, not as a selective TEV therapeutic.
-
Mitochondrial Repair in Diabetic Periodontitis
2026-08-16
The reference study develops an M1-macrophage-targeted, ROS-responsive hydrogel platform that delivers MitoQ to dysfunctional mitochondria in diabetic periodontitis. Its findings connect mitochondrial repair with reduced NLRP3 inflammasome activity, improved osteogenic responses, and enhanced periodontal bone regeneration, while also defining important questions for translation beyond the rat model.